These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
284 related articles for article (PubMed ID: 36349400)
1. Clinical trials on the pharmacological treatment of long COVID: A systematic review. Chee YJ; Fan BE; Young BE; Dalan R; Lye DC J Med Virol; 2023 Jan; 95(1):e28289. PubMed ID: 36349400 [TBL] [Abstract][Full Text] [Related]
2. The Neurological Manifestations of Post-Acute Sequelae of SARS-CoV-2 infection. Moghimi N; Di Napoli M; Biller J; Siegler JE; Shekhar R; McCullough LD; Harkins MS; Hong E; Alaouieh DA; Mansueto G; Divani AA Curr Neurol Neurosci Rep; 2021 Jun; 21(9):44. PubMed ID: 34181102 [TBL] [Abstract][Full Text] [Related]
3. Registered clinical trials investigating treatment of long COVID: a scoping review and recommendations for research. Ceban F; Leber A; Jawad MY; Yu M; Lui LMW; Subramaniapillai M; Di Vincenzo JD; Gill H; Rodrigues NB; Cao B; Lee Y; Lin K; Mansur RB; Ho R; Burke MJ; Rosenblat JD; McIntyre RS Infect Dis (Lond); 2022 Jul; 54(7):467-477. PubMed ID: 35282780 [TBL] [Abstract][Full Text] [Related]
4. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas. Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557 [TBL] [Abstract][Full Text] [Related]
5. Postacute Sequelae of Severe Acute Respiratory Syndrome Coronavirus 2 Infection. Hope AA; Evering TH Infect Dis Clin North Am; 2022 Jun; 36(2):379-395. PubMed ID: 35636906 [TBL] [Abstract][Full Text] [Related]
6. Testing the efficacy and safety of BIO101, for the prevention of respiratory deterioration, in patients with COVID-19 pneumonia (COVA study): a structured summary of a study protocol for a randomised controlled trial. Dioh W; Chabane M; Tourette C; Azbekyan A; Morelot-Panzini C; Hajjar LA; Lins M; Nair GB; Whitehouse T; Mariani J; Latil M; Camelo S; Lafont R; Dilda PJ; Veillet S; Agus S Trials; 2021 Jan; 22(1):42. PubMed ID: 33430924 [TBL] [Abstract][Full Text] [Related]
7. Neurological post-acute sequelae of SARS-CoV-2 infection. Takao M; Ohira M Psychiatry Clin Neurosci; 2023 Feb; 77(2):72-83. PubMed ID: 36148558 [TBL] [Abstract][Full Text] [Related]
8. A Scoping Review of Pharmacological Management of Postacute Sequelae of Severe Acute Respiratory Syndrome Coronavirus 2 Infection in 2021. Carson E; Hemenway AN Am J Ther; 2022 May-Jun 01; 29(3):e305-e321. PubMed ID: 35383586 [TBL] [Abstract][Full Text] [Related]
9. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial. Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543 [TBL] [Abstract][Full Text] [Related]
10. Therapeutic trials for long COVID-19: A call to action from the interventions taskforce of the RECOVER initiative. Bonilla H; Peluso MJ; Rodgers K; Aberg JA; Patterson TF; Tamburro R; Baizer L; Goldman JD; Rouphael N; Deitchman A; Fine J; Fontelo P; Kim AY; Shaw G; Stratford J; Ceger P; Costantine MM; Fisher L; O'Brien L; Maughan C; Quigley JG; Gabbay V; Mohandas S; Williams D; McComsey GA Front Immunol; 2023; 14():1129459. PubMed ID: 36969241 [TBL] [Abstract][Full Text] [Related]
11. Current landscape of long COVID clinical trials. Bhattacharya M; Chatterjee S; Saxena S; Nandi SS; Lee SS; Chakraborty C Int Immunopharmacol; 2024 May; 132():111930. PubMed ID: 38537538 [TBL] [Abstract][Full Text] [Related]
12. Immunologic and Autoimmune-Related Sequelae of Severe Acute Respiratory Syndrome Coronavirus 2 Infection: Clinical Symptoms and Mechanisms of Disease. Ramasamy A; Wang C; Brode WM; Verduzco-Gutierrez M; Melamed E Phys Med Rehabil Clin N Am; 2023 Aug; 34(3):623-642. PubMed ID: 37419536 [TBL] [Abstract][Full Text] [Related]
13. A systematic review of trials currently investigating therapeutic modalities for post-acute COVID-19 syndrome and registered on WHO International Clinical Trials Platform. Fawzy NA; Abou Shaar B; Taha RM; Arabi TZ; Sabbah BN; Alkodaymi MS; Omrani OA; Makhzoum T; Almahfoudh NE; Al-Hammad QA; Hejazi W; Obeidat Y; Osman N; Al-Kattan KM; Berbari EF; Tleyjeh IM Clin Microbiol Infect; 2023 May; 29(5):570-577. PubMed ID: 36642173 [TBL] [Abstract][Full Text] [Related]
14. Analysis of post COVID-19 condition and its overlap with myalgic encephalomyelitis/chronic fatigue syndrome. Sukocheva OA; Maksoud R; Beeraka NM; Madhunapantula SV; Sinelnikov M; Nikolenko VN; Neganova ME; Klochkov SG; Amjad Kamal M; Staines DR; Marshall-Gradisnik S J Adv Res; 2022 Sep; 40():179-196. PubMed ID: 36100326 [TBL] [Abstract][Full Text] [Related]
15. Markers of Immune Activation and Inflammation in Individuals With Postacute Sequelae of Severe Acute Respiratory Syndrome Coronavirus 2 Infection. Peluso MJ; Lu S; Tang AF; Durstenfeld MS; Ho HE; Goldberg SA; Forman CA; Munter SE; Hoh R; Tai V; Chenna A; Yee BC; Winslow JW; Petropoulos CJ; Greenhouse B; Hunt PW; Hsue PY; Martin JN; Daniel Kelly J; Glidden DV; Deeks SG; Henrich TJ J Infect Dis; 2021 Dec; 224(11):1839-1848. PubMed ID: 34677601 [TBL] [Abstract][Full Text] [Related]
16. Efficacy of hydroxychloroquine for post-exposure prophylaxis to prevent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection among adults exposed to coronavirus disease (COVID-19): a structured summary of a study protocol for a randomised controlled trial. Barnabas RV; Brown E; Bershteyn A; Miller RS; Wener M; Celum C; Wald A; Chu H; Wesche D; Baeten JM; Trials; 2020 Jun; 21(1):475. PubMed ID: 32493478 [TBL] [Abstract][Full Text] [Related]